Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

1. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.Blood transfusion = Trasfusione del sangue · 2014
   Guideline
2. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease.Blood · 2015
   Trial
3. Challenges in Metabolomics-Based Tests, Biomarkers Revealed by Metabolomic Analysis, and the Promise of the Application of Metabolomics in Precision Medicine.International journal of molecular sciences · 2022
   Review
4. Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?Annals of hematology · 2017
   Review
5. Diagnosis and Treatment of von Willebrand Disease and Rare Bleeding Disorders.Journal of clinical medicine · 2017
   Review
6. Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System.Haemophilia : the official journal of the World Federation of Hemophilia · 2017
   Article
7. Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A.Therapeutics and clinical risk management · 2016
   Review
8. Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B.Journal of blood medicine · 2016
   Review
9. Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders.Blood reviews · 2016
   Review
10. Human Parvovirus B19 and blood product safety: a tale of twenty years of improvements.Blood transfusion = Trasfusione del sangue · 2015
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

7 authors at 7 institutions in 4 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as